Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 Monotherapy and Combination Therapy in Advanced Gastric, GEJ, and Pancreatic Cancer
NCT05365581Phase 1Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2022
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies
- Countries
- 8
01
Overview
Phase 1, open-label trial of ASP2138 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma (PDAC) (10 arms), sponsored by Astellas Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days, Number of participants with Adverse Events at 27 months and 6 more. Started Jun 2022; status: recruiting.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05365581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365581.